Thrombolytic therapy of pulmonary embolism: A comprehensive review of current evidence

Chest

Volumn 115, Issue 6, 1999, Pages 1695-1707

  Arcasoy, Selim M ^a,c   Kreit, John W ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Fibrinolysis; Pulmonary embolism; Recombinant tissue type plasminogen activator; Streptokinase; Thrombolytic therapy; Urokinase

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE; UROKINASE;

ANTICOAGULANT THERAPY; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; GASTROINTESTINAL HEMORRHAGE; HUMAN; LUNG EMBOLISM; MORTALITY; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; REVIEW;

EID: 0033061284     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.115.6.1695     Document Type: Article

References (102)

1. 1 Coon WW, Willis PW. Deep venous thrombosis and pulmonary embolism: prediction, prevention and treatment. Am J Cardiol 1959; 4:611-621
2. 2 Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975; 17:259-270
3. 3 Bell WR, Simon TL. Current status of pulmonary thromboembolic disease: pathophysiology, diagnosis, prevention and treatment. Am Heart J 1982; 103:239-262
4. 4 Lilienfeld DE, Chan E, Ehland J, et al. Mortality from pulmonary embolism in the United States: 1962 to 1984. Chest 1990; 98:1067-1072
5. 5 Morrell MT, Dunnill MS. The post-mortem incidence of pulmonary embolism in a hospital population. Br J Surg 1968; 55:347-352
6. 6 Uhland H, Goldberg LM. Pulmonary embolism: a commonly missed clinical entity. Dis Chest 1964; 45:533-536
7. 7 Goldhaber SZ, Hennekens CH, Evans DA, et al. Factors associated with correct antemortem diagnosis of major pulmonary embolism. Am J Med 1982; 73:822-826
8. 8 Anderson FAJ, Goldberg RJ, Hosmer DW, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med 1991; 151:933-938
9. 9 Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960; 1:1309-1312
10. 10 Sasahara AA, Sharma GVRK, Barsamian EM, et al. Pulmonary thromboembolism: diagnosis and treatment. JAMA 1983; 249:2945-2950
11. 11 Hermann RE, Davis JH, Holden WD. Pulmonary embolism: a clinical and pathologic study with emphasis on the effect of prophylactic therapy with anticoagulants. Am J Surg 1961; 102:19-28
12. 12 Urokinase Pulmonary Embolism Trial: phase 1 results - a cooperative study. JAMA 1970; 214:2163-2172
13. 13 Urokinase-Streptokinase Embolism Trial: phase 2 results - a cooperative study. JAMA 1974; 229:1606-1613
14. 14 Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326:1240-1245
15. 15 Ferrari E, Baudouy M, Cerboni P, et al. Clinical epidemiology of venous thromboembolic disease: results of a French multicentre registry. Eur Heart J 1997; 18:685-691
16. 16 Lund O, Nielsen TT, Ronne K, et al. Pulmonary embolism: long-term follow-up after treatment with full-dose heparin, streptokinase or embolectomy. Acta Med Scand 1987; 221: 61-71
17. 17 Alpert JS, Smith R, Carlson J, et al. Mortality in patients treated for pulmonary embolism. JAMA 1976; 236:1477-1480
18. 18 Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism: Plasminogen Activator Italian Multicenter Study 2. J Am Coll Cardiol 1992; 20:520-526
19. 19 Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993; 341:507-511
20. 20 Kasper W, Konstantinides S, Geibel A, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997; 30:1165-1171
21. 21 Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation 1997; 96:882-888
22. 22 Monreal M, Ruiz J, Salvador R, et al. Recurrent pulmonary embolism: a prospective study. Chest 1989; 95:976-979
23. 23 Paraskos JA, Adelstein SJ, Smith RE, et al. Late prognosis of acute pulmonary embolism. N Engl J Med 1973; 289:55-58
24. 24 Phear D. Pulmonary embolism: a study of late prognosis. Lancet 1960; 2:832-835
25. 25 van Beek EJR, Kuijer PMM, Buller HR, et al. The clinical course of patients with suspected pulmonary embolism. Arch Intern Med 1997; 157:2593-2598
26. 26 Wheeler AP, Jaquiss RDB, Newman JH. Physician practices in the treatment of pulmonary embolism and deep vein thrombosis. Arch Intern Med 1988; 148:1321-1325
27. 27 Walker RHS, Jackson JA, Goodwin J. Resolution of pulmonary embolism. BMJ 1970; 4:135-139
28. 28 Goldhaber SZ, Visani L. The international cooperative pulmonary embolism registry. Chest 1995; 108:302-304
29. 29 Girard P, Mathieu M, Simonneau G, et al. Recurrence of pulmonary embolism during anticoagulant treatment: a prospective study. Thorax 1987; 42:481-486
30. 30 Dalen JE, Banas JS, Brooks HL, et al. Resolution rate of acute pulmonary embolism in man. N Engl J Med 1969; 280:1194-1199
31. 31 Fred HL, Axelrad MA, Lewis JM, et al. Rapid resolution of pulmonary thromboemboli in man: angiographic study. JAMA 1966; 196:1137-1139
32. 32 Tow DE, Wagner NHJ. Recovery of pulmonary arterial blood flow in patients with pulmonary embolism. N Engl J Med 1967; 276:1053-1059
33. 33 Cook DJ, Guyatt GH, Laupacis A, et al. Clinical recommendations using levels of evidence for antithrombotic agents. Chest 1995; 108(suppl):227S-230S
34. 34 Sharma GVRK, Cella G, Parisi AF, et al. Thrombolytic therapy. N Engl J Med 1982; 306:1268-1276
35. 35 Marder VJ, Sherry S. Thrombolytic therapy: current status. N Engl J Med 1988; 318:1512-1520
36. 36 Loscalzo J. An overview of thrombolytic agents. Chest 1990; 97(suppl):117S-123S
37. 37 Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1995; 108(suppl): 335S-351S
38. 38 Gulba DC, Bode C, Runge MS, et al. Thrombolytic agents: an overview. Ann Hematol 1996; 73:S9-S27
39. 39 Agnelli G, Parise P. Bolus thrombolysis in venous thromboembolism. Chest 1992; 101(suppl):172S-182S
40. 40 Agnelli G. Rationale for the bolus administration of fibrin-specific thrombolytic agents. Fibrinolysis & Proteolysis 1997; 11:23-27
41. 41 Agnelli G. Rationale for bolus t-PA therapy to improve efficacy and safety. Chest 1990; 97(suppl):161S-167S
42. 42 Agnelli G, Iorio A, Parise P, et al. Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. Blood Coagul Fibrinolysis 1997; 8:216-222
43. 43 Goldhaber SZ, Vaughan DE, Markis JE, et al. Acute pulmonary embolism treated with tissue plasminogen activator. Lancet 1986; 2:886-889
44. 44 Goldhaber SZ, Kessler CM, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988; 2:293-298
45. 45 Browse NL, James DCO. Streptokinase and pulmonary embolism. Lancet 1964; 11:1039-1043
46. 46 Genton E, Wolf PS. Urokinase therapy in pulmonary thromboembolism. Am Heart J 1968; 76:628-637
47. 47 Miller GAH, Gibson RV, Honey M, et al. Treatment of pulmonary embolism with streptokinase: a preliminary report. BMJ 1969; 1:812-815
48. 48 Miller GAH, Sutton GC, Kerr IH, et al. Comparison of Streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. BMJ 1971; 2:681-684
49. 49 Sautter RD, Emanuel DA, Fletcher FW, et al. Urokinase for the treatment of acute pulmonary thromboembolism. JAMA 1967; 202:215-218
50. 50 Sasahara AA, Cannilla JE, Belko JS, et al. Urokinase therapy in clinical pulmonary embolism: a new thrombolytic agent. N Engl J Med 1967; 277:1168-1173
51. 51 Tow DE, Wagner HN, Holmes RA. Urokinase in pulmonary embolism. N Engl J Med 1967; 277:1161-1167
52. 52 Dickie KJ, deGroot WJ, Cooley RN, et al. Hemodynamic effects of bolus infusion of urokinase in pulmonary thromboembolism. Am Rev Respir Dis 1974; 109:48-56
53. 53 Hirsh J, Hale GS, McDonald IG, et al. Streptokinase therapy in acute major pulmonary embolism: effectiveness and problems. BMJ 1968; 4:729-734
54. 54 Sharma GVRK, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. N Engl J Med 1980; 303:842-845
55. 55 Tibbutt DA, Davies JA, Anderson JA, et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. BMJ 1974; 1:343-347
56. 56 Ly B, Arnesen H, Erie H, et al. A controlled trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand 1978; 203:465-470
57. 57 Marini G, Di Ricco G, Rossi G, et al. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration 1988; 54:162-173
58. 58 PIOPED Investigators. Tissue plasminogen activator for the treatment of acute pulmonary embolism: a collaborative study by the PIOPED Investigators. Chest 1990; 97:528-533
59. 59 Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98:1473-1479
60. 60 Jerjes-Sanchez G, Ramirez-Rivera A, Garcia M de L, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis 1995; 2:227-229
61. 61 Sharma GVRK, Folland ED, McIntyre KM, et al. Longterm hemodynamic benefit of thrombolytic therapy in pulmonary embolic disease [abstract]. J Am Coll Cardiol 1990; 15:65A
62. 62 Meyer G, Sors H, Charbonnier B, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. J Am Coll Cardiol 1992; 19:239-245
63. 63 Goldhaber SZ, Kessler CM, Heit JA, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol 1992; 20:24-30
64. 64 Meneveau N, Schiele F, Vuillemenot A, et al. Streptokinase vs alteplase in massive pulmonary embolism: a randomized trial assessing right heart hemodynamics and pulmonary vascular obstruction. Eur Heart J 1997; 18:1141-1148
65. 65 Meneveau N, Schiele F, Metz D, et al. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol 1998; 31:1057-1063
66. 66 Tapson VF, Davidson CJ, Bauman R, et al. Rapid thrombolysis of massive pulmonary emboli without systemic fibrinogenolysis: intraembolic infusion of thrombolytic therapy [abstract]. Am Rev Respir Dis 1992; 145:A719
67. 67 Schwarz F, Stehr H, Zimmermann R, et al. Sustained improvement of pulmonary hemodynamics in patients at rest and during exercise after thrombolytic treatment of massive pulmonary embolism. Circulation 1985; 71:117-123
68. 68 Petitpretz P, Simmoneau G, Cerrina J, et al. Effects of a single bolus of urokinase in patients with life-threatening pulmonary emboli: a descriptive trial. Circulation 1984; 70:861-866
69. 69 Vujic I, Young JWR, Gobien RP, et al. Massive pulmonary embolism: treatment with full heparinization and topical low-dose streptokinase. Radiology 1983; 148:671-675
70. 70 Leeper KVJ, Popovich JJ, Lesser BA, et al. Treatment of massive acute pulmonary embolism: the use of low doses of intrapulmonary arterial streptokinase combined with full doses of systemic heparin. Chest 1988; 93:234-240
71. 71 Gallus AS, Hirsch J, Cade JF, et al. Thrombolysis with a combination of small doses of streptokinase and full doses of heparin. Semin Thromb & Hemost 1975; 2:14-32
72. 72 Edwards IR, MacLean KS, Dow JD. Low-dose urokinase in major pulmonary embolism. Lancet 1973; 2:409-413
73. 73 Barberena J. Intraarterial infusion of urokinase in the treatment of acute pulmonary thromboembolism: preliminary observations. AJR Am J Roentgenol 1983; 140:883-886
74. 74 Verstraete M, Miller GAH, Bounameaux H, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988; 77:353-360
75. 75 Fava M, Loyola S, Flores P, et al. Mechanical fragmentation and pharmacologic thrombolysis in massive pulmonary embolism. J Vasc Interv Radiol 1997; 8:261-266
76. 76 Stern M, Meyer G, Sors H. Urokinase versus tissue plasminogen activator in pulmonary embolism. Lancet 1988; 2:691-692
77. 77 Diehl J-L, Meyer G, Igual J, et al. Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism. Am J Cardiol 1992; 70:1477-1480
78. 78 Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis: an international multicenter randomized trial. Chest 1994; 106:718-724
79. 79 Goldhaber SZ, Feldstein ML, Sors H. Two trials of reduced bolus alteplase in the treatment of pulmonary embolism: an overview. Chest 1994; 106:725-726
80. 80 Sors H, Pacouret G, Azarian R, et al. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism: a randomized controlled multicenter trial. Chest 1994; 106:712-717
81. 81 Palla A, Pazzagli M, Manganelli D, et al. Resolution of pulmonary embolism: effect of therapy and putative age of emboli. Respiration 1997; 64:50-53
82. 82 Daniels LB, Parker JA, Patel SR, et al. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol 1997; 80:184-188
83. 83 Levine MN, Goldhaber SZ, Gore JM, et al. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest 1995; 108(suppl):291S-301S
84. 84 Kanter DS, Mikkola KM, Patel SR, et al. Thrombolytic therapy for pulmonary embolism: frequency of intracranial hemorrhage and associated risk factors. Chest 1997; 111: 1241-1245
85. 85 Lualdi JC, Goldhaber SZ. Right ventricular dysfunction after acute pulmonary embolism: pathophysiologic factors, detection, and therapeutic implications. Am Heart J 1995; 130: 1276-1282
86. 86 Goldhaber SZ. Pulmonary embolism thrombolysis: broadening the paradigm for its administration. Circulation 1997; 96:716-718
87. 87 Goldhaber SZ. Thrombolytic therapy in venous thromboembolism: clinical trials and current indications. Clin Chest Med 1995; 16:307-320
88. 88 Opinions regarding the diagnosis and management of venous thromboembolic disease: ACCP Consensus Committee on Pulmonary Embolism. Chest 1996; 109:233-237
89. 89 Goodman LR, Curtin JJ, Mewissen MW, et al. Detection of pulmonary embolism in patients with unresolved clinical and scintigraphic diagnosis: helical CT versus angiography. AJR Am J Roentgenol 1995; 164:1369-1374
90. 90 Remy-Jardin M, Remy J, Deschildre F, et al. Diagnosis of pulmonary embolism with spiral CT: comparison with pulmonary angiography and scintigraphy. Radiology 1996; 200: 699-706
91. 91 van Rossum AB, Pattynama PM, Ton ER, et al. Pulmonary embolism: validation of spiral CT angiography in 149 patients. Radiology 1996; 201:467-470
92. 92 van Rossum AB, Treurniet FEE, Kieft GJ, et al. Role of spiral volumetric computed tomographic scanning in the assessment of patients with clinical suspicion of pulmonary embolism and an abnormal ventilation/perfusion scan. Thorax 1996; 51:23-28
93. 93 Gefter WB, Hatabu H, Holland GA, et al. Pulmonary thromboembolism: recent developments in diagnosis with CT and MR imaging. Radiology 1995; 197:561-574
94. 94 Blum AG, Delfau F, Grignon B, et al. Spiral-computed tomography versus pulmonary angiography in the diagnosis of acute massive pulmonary embolism. Am J Cardiol 1994; 74:96-98
95. 95 Kasper W, Meinertz T, Henkel B, et al. Echocardiographic findings in patients with proved pulmonary embolism. Am Heart J 1986; 112:1284-1290
96. 96 Jardin F, Dubourg O, Gueret P, et al. Quantitative two-dimensional echocardiography in massive pulmonary embolism: emphasis on ventricular interdependence and leftward septal displacement. J Am Coll Cardiol 1987; 10:1201-1206
97. 97 Come PC, Kim D, Parker JA, et al. Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activator. J Am Coll Cardiol 1987; 10:971-978
98. 98 Come PC. Echocardiographic evaluation of pulmonary embolism and its response to therapeutic interventions. Chest 1992; 101(suppl):151S-162S
99. 99 McConnell MV, Solomon SD, Rayan ME, et al. Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol 1996; 78:469-473
100. 100 Thrombolytic therapy in thrombosis: a National Institutes of Health consensus development conference. Ann Intern Med 1980; 93:141-144
101. 101 Goldhaber SZ. Contemporary pulmonary embolism thrombolysis. Chest 1995; 107(suppl):45S-51S
102. 102 Goldhaber SZ. Recent advances in the diagnosis and lytic therapy of pulmonary embolism. Chest 1991; 99(suppl): 173S-179S